Summary:
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.
This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.
Qualified Participants Must:
• Be age 18-65
•
Subjects with both a diagnosis of recurrent major depressive disorder, and in a current major depressive episode of 8 weeks or more in duration
•
Subjects must have reported a history for the current major depressive episode of an inadequate response to 1 or 2 adequate antidepressant treatments
Qualified Participants May Receive:
Compensation for time and travel, study-related treatment and investigational drug or placebo.